QS/1 integrates with Appriss Health’s NARxCHECK
SPARTANBURG, S.C. — In an effort to make reporting the dispensing of controlled substances easier for it pharmacy partners, QS/1 announced Monday that it had become the first pharmacy management software provider to offer integration with Apriss Health’s NARxCHECK. NARxCheck is a tool designed to fight prescription drug abuse by offering pharmacies real-time access to data collected by prescription drug monitoring programs.
QS/1’s integration facilitates the exchange of information between the pharmacy and Apriss Health to allow NARxCHECK to analyze a patient’s prescription profile against various PDMPs to determine whether a patient might be obtaining multiple prescriptions for controlled substances.
“It’s a unique exchange of information that can alert of possible overuse or abuse of prescription drugs,” South Carolina Pharmacy Association president Ed Vess said. “Rather than just filling the prescription and sending the information to the state PDMP, NARxCHECK shows the pharmacy staff all controlled substance prescriptions that the patient has been previously provided. It allows the pharmacist a chance to make an informed decision on whether they should fill the prescription, ask a few more questions, or refuse to fill the prescription.”
NARxCheck allows for the possibility for PMP data to be shared across state line if a patient is filling prescriptions in other states where information is exchanged with Apriss Health.
“This risk assessment is invaluable in the effort to reduce inappropriate access to opioids, improve patient safety and prevent addiction and abuse of prescription drugs,” Vess added.
Alvogen, Natco launch first Tamiflu generic
PINE BROOK, N.J.and HYDERABAD, India — Alvogen and Natco Pharma on Monday announced the launch of their generic of Tamiflu (oseltamivir phosphate) capsules, the first generic of the flu treatment to hit the U.S. market. The generic was approved by the Food and Drug Administration in August.
The launch of oseltamivir phosphate is great news for U.S. patients, who will finally have access to a more affordable alternative to Tamiflu. It is also an important milestone for our U.S. business. The launch demonstrates our ability to move quickly and we are proud to partner with Natco to bring this product to market.”
The drug had U.S. sales of about $403 million for the 12 months ending December 2015, according to QuintilesIMS data.
Endo begins shipping first Zetia generic
DUBLIN — Endo announced Thursday that its Par Pharmaceutical had begun shipping the first generic version of Zetia (ezetimibe) tablets. The drug is indicated to reduce elevated LDL cholesterol in patients with hyperlipidemia.
Par’s generic is entitled to market exclusivity based on the first-to-file status of the application filed by its licensing partners, Glenmark Pharmaceuticals USA.
The drug will be available in 10-mg dosage strength. U.S. sales of Zetia were bout $2.61 billion for the 12 months ended September 30.
Loading Post Please Wait...